Talis Biomedical Corp Stock Today

TLIS Stock  USD 8.62  0.02  0.23%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 83

 
High
 
Low
Very High
Talis Biomedical is selling for under 8.62 as of the 25th of July 2024; that is 0.23% down since the beginning of the trading day. The stock's lowest day price was 8.3. Talis Biomedical has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Talis Biomedical Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of May 2023 and ending today, the 25th of July 2024. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
12th of February 2021
Category
Healthcare
Classification
Health Care
Talis Biomedical Corporation operates as a molecular diagnostic company. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California. Talis Biomedical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 1.82 M outstanding shares of which 14.66 K shares are at this time shorted by private and institutional investors with about 2.4 trading days to cover. More on Talis Biomedical Corp

Moving against Talis Stock

  0.51EW Edwards Lifesciences Corp Sell-off TrendPairCorr
  0.5GH Guardant HealthPairCorr
  0.48LH LaboratoryPairCorr

Talis Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President OfficerAndrew Lukowiak
Thematic IdeaDrugs (View all Themes)
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Drugs, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.0040.0042
Notably Down
Slightly volatile
Total Current Liabilities11.7 M8.8 M
Significantly Up
Slightly volatile
Non Current Liabilities Total19.4 M20.5 M
Notably Down
Very volatile
Total Assets141 M98.3 M
Way Up
Slightly volatile
Total Current Assets122.7 M77.7 M
Way Up
Slightly volatile
Debt Levels
Talis Biomedical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Talis Biomedical's financial leverage. It provides some insight into what part of Talis Biomedical's total assets is financed by creditors.
Liquidity
Talis Biomedical Corp currently holds 19.67 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Talis Biomedical Corp has a current ratio of 12.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Talis Biomedical's use of debt, we should always consider it together with its cash and equity.

Depreciation

3.23 Million
Talis Biomedical Corp (TLIS) is traded on NASDAQ Exchange in USA. It is located in 3400 Bridge Parkway, Redwood City, CA, United States, 94065 and employs 99 people. Talis Biomedical is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.74 M. Talis Biomedical Corp conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 1.82 M outstanding shares of which 14.66 K shares are at this time shorted by private and institutional investors with about 2.4 trading days to cover. Talis Biomedical Corp currently holds about 165.37 M in cash with (53.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.21.
Check Talis Biomedical Probability Of Bankruptcy
Ownership Allocation
30% of Talis Biomedical Corp outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check Talis Ownership Details

Talis Stock Institutional Holders

InstituionRecorded OnShares
Adar1 Capital Management Llc2024-03-31
300
Advisor Group Holdings, Inc.2024-03-31
122
Ubs Group Ag2024-03-31
120
Larson Financial Group, Llc2024-03-31
14.0
Wells Fargo & Co2024-03-31
13.0
Jpmorgan Chase & Co2024-03-31
3.0
Qube Research & Technologies2024-03-31
2.0
Royal Bank Of Canada2023-12-31
0.0
New England Capital Financial Advisors Llc2023-12-31
0.0
Baker Bros Advisors Lp2024-03-31
508.3 K
Greenlight Capital, Inc2023-12-31
149.1 K
View Talis Biomedical Diagnostics

Talis Biomedical Historical Income Statement

At this time, Talis Biomedical's Net Interest Income is comparatively stable compared to the past year. Interest Income is likely to gain to about 50.4 K in 2024, whereas Selling General Administrative is likely to drop slightly above 25.8 M in 2024. View More Fundamentals

Talis Stock Against Markets

Talis Biomedical Corporate Management

Roger MoodyChief OfficerProfile
Gillian GreenCompany SecretaryProfile
Margaret MSControllerProfile
Rustem IsmagilovCoFounder DirectorProfile
Rebecca MarkovichInterim OfficerProfile
Jill GreenSenior LegalProfile

Additional Tools for Talis Stock Analysis

When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.